Pasithea Therapeutics (NASDAQ:KTTA) Posts Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) posted its quarterly earnings data on Monday. The company reported ($2.41) EPS for the quarter, Zacks reports.

Pasithea Therapeutics Trading Up 0.8 %

NASDAQ:KTTA opened at $1.25 on Tuesday. The stock has a 50-day simple moving average of $1.67 and a 200 day simple moving average of $2.95. Pasithea Therapeutics has a one year low of $0.92 and a one year high of $9.25.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.